Biography:
Thomas Bernd Dschietzig studied Medicine at Charité, the Medical Faculty of the Humboldt University of Berlin, Germany, and is a specialist of Internal Medicine focused on cardiovascular research. His lab and clinical work have been focused on the study of physiology and pathophysiology of the naturally occurring peptide hormone human relaxin-2. He is Chief Executive Officer and co-founder of Relaxera, a pharma company dedicated to develop synthetic human relaxin-2 for chronic clinical use in cardio-vascular disease, especially in Heart Failure with Preserved Ejection Fraction, HFpEF.
Title : The development of human relaxin-2 for heart failure with preserved ejection fraction, HFpEF